0001415889-24-001829.txt : 20240125
0001415889-24-001829.hdr.sgml : 20240125
20240125200009
ACCESSION NUMBER: 0001415889-24-001829
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240123
FILED AS OF DATE: 20240125
DATE AS OF CHANGE: 20240125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WILSON ROBERT N
CENTRAL INDEX KEY: 0001189022
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39538
FILM NUMBER: 24563784
MAIL ADDRESS:
STREET 1: C/O JOHNSON & JOHNSON
STREET 2: ONE JOHNSON PLAZA
CITY: NEW BRUNSWICK
STATE: NJ
ZIP: 08933
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CalciMedica, Inc.
CENTRAL INDEX KEY: 0001534133
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 452120079
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 505 COAST BOULEVARD SOUTH
STREET 2: SUITE 307
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: 858-952-5500
MAIL ADDRESS:
STREET 1: 505 COAST BOULEVARD SOUTH
STREET 2: SUITE 307
CITY: LA JOLLA
STATE: CA
ZIP: 92037
FORMER COMPANY:
FORMER CONFORMED NAME: CalciMedica, Inc. /DE/
DATE OF NAME CHANGE: 20230322
FORMER COMPANY:
FORMER CONFORMED NAME: GRAYBUG VISION, INC.
DATE OF NAME CHANGE: 20170717
FORMER COMPANY:
FORMER CONFORMED NAME: GRAYBUG, Inc.
DATE OF NAME CHANGE: 20150303
4
1
form4-01252024_080102.xml
X0508
4
2024-01-23
0001534133
CalciMedica, Inc.
CALC
0001189022
WILSON ROBERT N
C/O CALCIMEDICA, INC.
505 COAST BLVD. S. #307
LA JOLLA
CA
92037
true
false
false
false
0
Common Stock
2024-01-23
4
A
0
68314
4.2665
A
250475
D
Warrant
5.36
2024-01-23
4
A
0
34157
0.125
A
2024-01-23
2024-12-31
Common Stock
34157
34157
D
Warrant
7.15
2024-01-23
4
A
0
34157
0.125
A
2024-01-23
2026-12-31
Common Stock
34157
34157
D
The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.
The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.
/s/ John Dunn, Attorney-in-Fact
2024-01-25